Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

PURPOSE: Vorinostat is the first US Food and Drug Administration–approved histone deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell lymphoma. We conducted a phase I study to determine the maximum-tolerated dose and pharmacokinetics of vorinostat in patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ramalingam, Suresh S., Kummar, Shivaani, Sarantopoulos, John, Shibata, Stephen, LoRusso, Patricia, Yerk, Mara, Holleran, Julianne, Lin, Yan, Beumer, Jan H., Harvey, R. Donald, Ivy, S. Percy, Belani, Chandra P., Egorin, Merrill J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2988640/
https://ncbi.nlm.nih.gov/pubmed/20837947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.2307
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados